

**DTIC FILE COPY**

2

AD \_\_\_\_\_

AD-A201 913

**FUNCTIONAL CARDIORESPIRATORY TOXICITY SCREENING OF CANDIDATE  
ANTIPARASITIC DRUGS AND ANTIDOTES FOR CHEMICAL POISONS**

**Subtitle: STUDY OF THE EFFECTS OF DRUGS UPON THE  
CARDIOVASCULAR AND RESPIRATORY SYSTEMS**

**ANNUAL REPORT**

**Robert W. Caldwell**

**Clinton B. Nash**

**June 1, 1988**

**(November 1, 1986 - October 31, 1987)**

**Supported by**

**U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND**

**Fort Detrick, Frederick, Maryland 21701-5012**

**Contract No: DAMD17-86-C-6009**

**Medical College of Georgia Research Institute, Inc.  
Medical College of Georgia  
Augusta, GA 30912-0059**

**DOD DISTRIBUTION STATEMENT**

**Approved for public release; distribution unlimited.**

**The findings in this report are not to be construed as an official Department of the  
Army position unless so designated by other authorized document.**

**DTIC  
ELECTE  
NOV 30 1988  
S E D**

**88 11 30 009**

## REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION Unclassified			1b. RESTRICTIVE MARKINGS		
2a. SECURITY CLASSIFICATION AUTHORITY			3. DISTRIBUTION / AVAILABILITY OF REPORT Approved for public release; distribution unlimited.		
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE			4. PERFORMING ORGANIZATION REPORT NUMBER(S)		
4. PERFORMING ORGANIZATION REPORT NUMBER(S)			5. MONITORING ORGANIZATION REPORT NUMBER(S)		
6a. NAME OF PERFORMING ORGANIZATION Medical College of Georgia Research Institute, Inc.		6b. OFFICE SYMBOL (If applicable)	7a. NAME OF MONITORING ORGANIZATION		
6c. ADDRESS (City, State, and ZIP Code) Department of Pharmacology and Toxicology Medical College of Georgia Augusta, Georgia 30912-2300			7b. ADDRESS (City, State, and ZIP Code)		
8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command		8b. OFFICE SYMBOL (If applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER Contract No. DAMD 17-86-C-6009		
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, MD 21701-5012			10. SOURCE OF FUNDING NUMBERS		
			PROGRAM ELEMENT NO. 63764A	PROJECT NO. 3M6- 3764D995	TASK NO. AB
			WORK UNIT ACCESSION NO. 043		
11. TITLE (Include Security Classification) Functional Cardiorespiratory Toxicity Screening of Candidate Antiparasitic Drugs and Antidotes for Chemical Poisons.					
12. PERSONAL AUTHOR(S) Caldwell, Robert W. and Nash, Clinton B.					
13a. TYPE OF REPORT Annual		13b. TIME COVERED FROM 1 Nov 86 TO 31 Oct 87		14. DATE OF REPORT (Year, Month, Day) 1988 June 1	
15. PAGE COUNT					
16. SUPPLEMENTARY NOTATION Subtitle: Study of the Effects of Drugs Upon the Cardiovascular and Respiratory Systems.					
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)		
FIELD	GROUP	SUB-GROUP	chloroquine, mefloquine,		
06	15		pyridostigmine bromide, automaticity (JES)		
06	15		rhythmicity, RAI; RAV		
19. ABSTRACT (Continue on reverse if necessary and identify by block number) During this past year we have 1. completed experimental work on the <u>Effects of Chloroquine and Mefloquine Individually in Combination Upon Automaticity, Rhythmicity and Dynamics of the Heart</u> . Summary attached. 2. Written a protocol to study the <u>Effects of Mefloquine and Pyridostigmine Individually and in Combination Upon Cardiac Automaticity</u> . A copy of this protocol is attached. <i>Report</i>					
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION Unclassified		
22a. NAME OF RESPONSIBLE INDIVIDUAL Ms. Virginia M. Miller			22b. TELEPHONE (Include Area Code) (301) 663-7325		22c. OFFICE SYMBOL SGRD-RMI-S

SUMMARY

1. Completed experimental work on the Effects of Chloroquine and Mefloquine Individually and in Combination Upon Automaticity, Rhythmicity, and Dynamics of the Heart. Summary is attached.
  
2. During this past year we have: written a protocol to study The Effects of Mefloquine and pyridostigmine Individually and in Combination Upon Cardiac Automaticity. A copy of this protocol (submitted on 18 September 1987) is attached.

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	



## FOREWORD

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIR Publication No. 86-23, Revised 1985).

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

## TABLE OF CONTENTS

	Page
Report Documentation Page	2
Foreword	4
I. Summary - The Effects of Chloroquine and Mefloquine Individually and in Combination Upon Automaticity, Rhythmicity and Dynamics of the Heart.	6
II. Protocol - The Effects of Mefloquine and Pyridostigmine Individually and in Combination Upon Cardiac Automaticity.	10

## SUMMARY

Twenty-four adult beagle dogs anesthetized with pentobarbital Na were injected with formalin into the A-V node and adjoining bundle of His to attain complete heart block. This was done in order to observe separately the actions of chloroquine and mefloquine on the automaticity of both the atria and the ventricles. Chloroquine and mefloquine are both antimalarial drugs which are known to interfere with normal cardiac impulse formation and contractility. Since the possibility exists that mefloquine may be administered following chloroquine treatment where resistance to chloroquine has arisen, it was deemed necessary to test the two drugs in combination to determine if any antagonism, additivity, or potentiation of effects on cardiac automaticity (rhythm) occur.

Thirty minutes after inducing heart block, baseline measurements were taken for intrinsic rates for both atria and ventricles, arterial blood pressure, and left ventricular pressure. Following these measurements, the atria and ventricles were simultaneously overdriven electrically for 2 minutes using square wave DC pulses of 5 msec duration at a voltage 3 times the driving threshold. The atria were driven at 200 beats/minute and the ventricles at 150 beats/minute. These frequencies represent overdrive values considering the normal intrinsic rates.

Immediately following overdrive, simultaneous assessments of atrial and ventricular automaticity were made by measuring the period of asystole (period following cessation of stimulation until first depolarization), the period for the first 10 depolarizations, and the number of depolarizations in the first 30 second period.

Section I

After drug administration, this overdrive process was repeated and measurements taken every 10 minutes up to 100 minutes. The drugs given were either the control (5% dextrose in water -D5W),  $ED_{50}$  chloroquine in D5W,  $ED_{50}$  mefloquine in D5W, or a combination of  $\frac{1}{2}$   $ED_{50}$  chloroquine +  $\frac{1}{2}$   $ED_{50}$  mefloquine in D5W.

It was found that four of our experimental variables exhibited responses to chloroquine, mefloquine or the drug combination. Intrinsic atrial rate and the number of atrial beats in 30 sec following overdrive were significantly depressed by all three treatments. Left ventricular dp/dt was depressed only by chloroquine; no other treatments affected dp/dt. For each of these variables, there were no differences among the treatment groups, only differences between treatment groups and the control group. For all other variables, neither of the drugs alone nor the combination produced any discernable effects.

In the case of all measured variables, the values or responses for the combination treatment group were not different from those in the groups given mefloquine or chloroquine alone. Therefore, by Gaddum's definitions of possible drug interactions, only simple addition of effects occurred when mefloquine and chloroquine were combined.



Section II

## INTRODUCTION

Mefloquine is an antimalarial drug that is known to interfere with normal cardiac impulses and contractility (Arora and Lai, 1963; Hemwell and Di Palma, 1979; Caldwell and Nash, 1977). Pyridostigmine bromide is a reversible inhibitor of acetylcholinesterase activity which increases the plasma and tissue half-life of acetylcholine. The resulting biological effect of pyridostigmine upon the cardiovascular system is reduced heart rate (Caldwell, et al., 1986). Preliminary studies in our laboratory have shown the mefloquine reduced the automaticity of the ventricle but not that of the atria. On the other hand, pyridostigmine decreased automaticity in the atria, but not in the ventricle (Caldwell, et al., 1986). The possibility exists that pyridostigmine may be administered following treatment with mefloquine, therefore any combined effects that may exist need to be revealed.

## PURPOSE

To determine whether a combination of these drugs will augment, antagonize, or have no influences upon cardiovascular variables as compared to each drug independently administered.

## EXPERIMENTAL PREPARATION

The dogs used in this study were divided into four groups of six each as follows:

1. Mefloquine - 8 mg/kg
2. Pyridostigmine - 2 mg/kg
3. Combination - Mefloquine (4 mg/kg) - pyridostigmine (1 mg/kg)
4. Vehicle control

Pure bred beagle dogs of either six, 9 months and older, weighing between 9.0 and 14.0 kg will be purchased from Riglan Animal Care Systems (Mt. Horan, WI). This company guarantees that all dogs will be in excellent

health upon arrival at the Medical College of Georgia Vivarium. The dogs will be kept in quarantine and under the care of Medical College of Georgia veterinarians who will verify their excellent health upon receipt and thereafter.

Sodium pentobarbital, 30 mg/kg intravenously, will be used to anesthetize the dogs. Supplemental doses will be administered as needed to maintain proper anesthesia.

A T-shaped cannula will be inserted into the trachea and the dog will be placed on a Harvard respirator breathing room air at 25 ml/kg tidal volume at a rate of 10-15 breaths/min.

A femoral artery will be catheterized with polyethylene tubing filled with heparinized saline advanced to the thoracic aorta for measurement of arterial blood pressure via a Statham P23AC pressure transducer.

One cephalic vein will be catheterized for administration of drug. In experiments where two drugs are given, both cephalic veins will be used and the two drugs infused simultaneously.

The heart will be exposed via a mid-sternal chest incision and the pericardium removed. Two small plexiglass plates (1.5 x 0.5 cm) each having four platinum electrodes will be sewn to a convenient site upon the surface of the right ventricle and right atrial appendage to provide good contact. Two electrodes from each plate will be used to record the electrogram. The two remaining electrodes will be used to drive the atria and ventricles at separate rates using two Grass stimulators, model SD9. The electrograms from the atrium and the ventricle will be recorded on a Grass Polygraph along with the blood pressure.

In a previous study (Caldwell and Nash, 1977) it was determined that a dose of 8 mg/kg of mefloquine gave cardiovascular responses near the middle of the dose-response curves. This dose produced a reduction in automaticity

which occurred only in the ventricles, and no apparent change occurred in the atria.

A dose of 5 mg/kg of pyridostigmine was determined to reduce heart rate and acetylcholinesterase activity to a point just short of death (Caldwell, et al., 1986). A dose of 2 mg/kg produced intermediate responses and was, therefore, used as a basis for our preliminary studies of automaticity. Experiments on automaticity using 2 mg/kg of pyridostigmine did show reduced automaticity in the atria.

Drug Preparation and Administration: Mefloquine will be supplied by WRAIR along with an assay report. Mefloquine is water soluble to some degree (2 mg/ml) and will be dissolved and administered in 5% dextrose in water. Adequate supplies of pyridostigmine in the form of Mestinon® will be furnished by WRAIR along with an assay report. Mestinon® is in liquid form and will be diluted in 5% dextrose in water. Both drugs will be administered intravenously via a Cole-Palmer variable speed pump in a constant volume of 4 ml/kg over 10 minutes.

A-V Conduction blockade: Complete heart block by the method of Steiner and Kovalik (1968) will be achieved by injecting 0.1 ml of 40% formaldehyde into the atrial septum at the level of the A-V node and the adjoining common bundle of His. Injection will be accomplished via a 25 gauge needle placed at a depth of 0.5 to 1.0 cm below the groove between the atrium and aorta. Complete heart block is verified by lead II ECG recording.

Procedure: Our procedure is patterned after Afonso et al., (1972) and Korte and Nash (1978). Following surgery and A-V block, the dog will be allowed to equilibrate for approximately 30 minutes.

The atria and ventricles will be simultaneously overdriven for 2 minutes with a square wave D.C. pulse of 5 msec duration at a voltage strength 3 times the driving threshold (Korte and Nash, 1978). Threshold

will be determined by the minimum voltage required to drive the atria and ventricles. We will drive the atria at 200 beats/min and the ventricles at 150 beats/min. Immediately following the period of overdrive, assessment of automaticity will be made as follows: (or the atria and ventricles independently).

1. The time required for the first 10 beats following cessation of stimulation.
2. The number of beats that occur in the 30 second period following the cessation of stimulation.
3. Asystole period in seconds following cessation of stimulation until first heart beat.

In addition to the above measurements, we will record intrinsic heart rate and systolic and diastolic blood pressure.

Observation period: Baseline values will be taken at -30 min. and 0 time before infusing the drug. The experiment will continue for 3 hours following drug administration with assessments of automaticity taken every 30 minutes. Prior to each overdrive period, the intrinsic heart rates of both the ventricles and atria will be determined along with arterial blood pressure.

Analysis of data: Each of the four experimental groups will be comprised of six dogs. Following all necessary experiments, the value of each time point for each individual in each treatment group will be plotted over the 180 minute period of the experiment. The data over the observation period for each dog will then be averaged and divided by the mean of the respective baseline (zero time) to obtain the change in response ratio following treatment. The ratios for each variable from each treatment will be plotted as a linear horizontal sensitivity graphic. These plots will furnish a visual impression of the treatment effects. The statistical

analysis will involve a one-way analysis of variance for significance within the overall experiment, followed by use of the Newman-Keuls technique to establish which changes are significant (Winer, 1971).


This data treatment will help us to decide which of the following possible interactions may have occurred:

1. Potentiation ( $0.5 A + 0.5 B > \text{the larger of } A \text{ or } B$ )
2. Antagonism ( $0.5 A + 0.5 B < \text{the smaller of } A \text{ or } B$ )
3. Simple Addition ( $0.5 A + 0.5 B = A \text{ or } B$ , or a value between A and B)


Upon completion of a test, each dog shall be euthanized using an over-dose of pentobarbital; monitoring shall be continued until cardiac and respiratory standstill have been observed.

- 
1. The conduct of these studies shall comply with the GOOD LABORATORY PRACTICES (GLP) regulations as published in the Federal Register, Volume 43 (247), 22 December 1978, Part II, pp 59, 986-60,020 (and all subsequent addenda).

2. In the proposed studies, the investigators will adhere to the principles outlined in the current "Guide for the Care and Use of Laboratory Animals", Public Health Service National Institute of Health, NIH Publication No. 85-23, Revised 1985.



Robert W. Caldwell, Ph.D.



Clinton B. Nash, Ph.D.



M.A. Chryssanthis, B.S.



K.U. Malik, Ph.D., D.Sc.

Quality Assurance Officer

REFERENCES

1. Afonso, Skoda, Hansing, C.E., Ansfield, T.J., Berndt, T.B., and Rowe, G.G. Enhancement of cardiovascular effects of glucagon by aminophylline. *Cardiovasc. Res.* 6:235-239, 1972.
2. Arora, R.B. and Lai, A. Antimalarial drugs on the automaticity of sinoauricular and atrioventricular nodes. *Ind. J. Med. Res.* 51:725-731, 1963.
3. Caldwell, R.W. and Nash, C.B. Cardiovascular and pulmonary actions of mefloquine HCl. *Toxicol. Appl. Pharmacol.* 40:473, 1977.
4. Caldwell, R.W., Nash, C.B., Chyrssanthis, M.A., Thomas, T.R. and Rieck, C. Cardiovascular and pulmonary effects of intravenous pyridostigmine. Bromide infusion in the dog; Correlation with blood cholinesterase inhibition. Interim Report Number 9, Department of Pharmacology, University of Tennessee, 1986.
5. Caldwell, R.W., Nash, C.B. and Chryssanthis, M.A. Effects of chloroquine and mefloquine individually and in combination upon automaticity, rhythmicity and dynamics of the heart. Study Report Number 10, Department of Pharmacology, University of Tennessee, 1987.
6. Gaddum, J.H. *Pharmacology*, 5th ed., London, Oxford University Press, pp. 504-508, 1959.
7. Hemwell, E. and DiPalma, J.R., Jr. Cardiovascular and antiarrhythmic effects of mefloquine. *Pharmacol.* 21:200, 1979.
8. Korte, D.W., Jr. and Nash, C.B. The effect of a combination of quinidine and propranolol upon atrial and ventricular automaticity in dogs. *J. Pharmacol. Exp. Ther.* 204:303-311, 1978.
9. Steel, R.G.D. and Torrie, J.H. *Principles and Procedures of Statistics*. McGraw-Hill Book Company, New York, 1960.



10. Steiner, C. and T.W. Kovalik. A simple technique for production of chronic complete heart block in dogs. J. App. Physiol. 25:631-632, 1968.
11. Winer, B.J. Statistical principles in experimental design, Second Edition, McGraw Hill Book Co., New York, 1971.

## DISTRIBUTION LIST

5 Copies	Director Walter Reed Army Institute of Research Walter Reed Army Medical Center ATTN: SGRD-UWZ-C Washington, DC 20307-5100
1 Copy	Commander US Army Medical Research and Development Command ATTN: SGRD-RMI-S Fort Detrick, Frederick, Maryland 21701-5012
2 Copies	Defense Technical Information Center (DTIC) ATTN: DTIC-DDAC Cameron Station Alexandria, VA 22304-6145
1 Copy	Dean School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814-4799
1 Copy	Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM Fort Sam Houston, TX 78234-6100